Teligene

Teligene (Suzhou Teligene Biotechnology Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2011 in Suzhou, China by Dr. Zhang Dawei, a former chief scientist at Amgen. The company focuses on the design, research and industrialization of innovative small-molecule targeted drugs for oncology, with a pipeline addressing lung cancer, breast cancer, and head and neck squamous cell carcinoma. Teligene US LLC is a wholly owned US subsidiary advancing these candidates through clinical development. It was surfaced as a portfolio company of idg-capital and added to the API Evangelist network for enrichment; as a drug-development biotech it publishes no public API, developer portal, or machine-readable API surface.

Teligene is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Biotechnology, Pharmaceuticals, and Oncology.

🌐 Visit website 📡 Source on GitHub
2.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0
0 APIs
CompanyHealthcareBiotechnologyPharmaceuticalsOncologyDrug Discovery

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0
Composite quality — 2.2/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.0 / 17
Access Clarity 0.0 / 17
Operational Transparency 0.0 / 11
Contract Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 0.0 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
Documented Reversibility 0 / 6
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/teligene: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 2

The organization behind the API

Website
Website
 LinkedIn
LinkedIn

Source (apis.yml)

apis.yml Raw ↑ 
aid: teligene
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/teligene.png
name: Teligene
description: Teligene (Suzhou Teligene Biotechnology Co., Ltd.) is a clinical-stage biopharmaceutical company founded in 2011
  in Suzhou, China by Dr. Zhang Dawei, a former chief scientist at Amgen. The company focuses on the design, research and
  industrialization of innovative small-molecule targeted drugs for oncology, with a pipeline addressing lung cancer, breast
  cancer, and head and neck squamous cell carcinoma. Teligene US LLC is a wholly owned US subsidiary advancing these candidates
  through clinical development. It was surfaced as a portfolio company of idg-capital and added to the API Evangelist network
  for enrichment; as a drug-development biotech it publishes no public API, developer portal, or machine-readable API surface.
url: https://raw.githubusercontent.com/api-evangelist/teligene/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- idg-capital
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Healthcare
- Biotechnology
- Pharmaceuticals
- Oncology
- Drug Discovery
apis: []
common:
- type: Website
  url: https://www.teligenebio.cn/en/
- type: LinkedIn
  url: https://www.linkedin.com/company/teligene-us
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-21'
  status: nochange
  artifacts_added: 0
  pass: local-v1